Platelet glycoprotein IIb/IIIa inhibitors: Recognition of a two-edged sword?

Circulation

Volumn 106, Issue 3, 2002, Pages 379-385

  Quinn, Martin J ^a   Plow, Edward F ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Glycoproteins; Platelets; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CD40 LIGAND; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; HEPARIN; LAMIFIBAN; ORBOFIBAN; PLACEBO; SIBRAFIBAN; TIROFIBAN; XEMILOFIBAN;

APOPTOSIS; BLEEDING; BLOOD VESSEL OCCLUSION; CELL INTERACTION; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT INDICATION;

ACUTE DISEASE; ADMINISTRATION, ORAL; BLOOD PLATELETS; CD40 LIGAND; CORONARY DISEASE; HUMANS; INFLAMMATION; INFUSIONS, INTRAVENOUS; MODELS, CARDIOVASCULAR; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; SYNDROME; TREATMENT OUTCOME;

EID: 0037118664     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000019581.22812.B2     Document Type: Review

References (55)

1. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
2. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting
3. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation
4. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
5. Long-term mortality benefit of abciximab in percutaneous intervention
6. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis
7. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials
8. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial
9. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
10. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial
11. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events
12. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
13. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes
14. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes
15. Oral glycoprotein IIb/IIIa inhibitors: Why don't they work?
16. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
17. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IlIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network
18. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes
19. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
20. Glycoprotein IIb/IIIa inhibitors in the medical management of unstable ischemic syndromes without persistent ST segment elevation: A meta-analysis of the randomized trials
21. Comparison of two platelet glycoprotein IIb/lIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
22. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
23. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
24. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes
25. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: The PARAGON-B troponin T substudy
26. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease
27. Angiographic findings in patients with refractory unstable angina according to troponin T status
28. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions
29. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study
30. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization with stent placement: The TARGET study
31. One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I)
32. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease
33. Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab
34. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion
35. Association between ligandinduced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signaling
36. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors
37. Evidence of platelet activation during treatment with a GP IIb/IIIa antagonist in patients presenting with acute coronary syndromes
38. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation
39. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation
40. Activated platelets mediate inflammatory signaling by regulated interleukin Ibeta synthesis
41. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
42. CD40L stabilizes arterial thrombi by a 3 integrin-dependent mechanism
43. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression
44. Circulating activated platelets assist THP-1 monocytoid/endotheliaI cell interaction under shear stress
45. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction
46. Platelet-leukocyte cross talk in whole blood
47. GP IIb-IIIa antagonists demonstrate a dose-dependent inhibition and potentiation of soluble CD40L (CD154) release during platelet stimulation
48. Evaluation of the culprit plaque and the physiological significance of coronary atherosclerotic narrowings
49. An elevated white blood cell count is an independent predictor of mortality in patients with acute coronary syndromes
50. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: Effects of an early invasive or noninvasive strategy
51. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
52. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
53. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention